PDF(Pubmed)
Abstract：
Use of montelukast, as a cause of neuropsychiatric events, in patients with asthma or allergic rhinitis is controversial, and comprehensive statistical analyses verifying this relationship remain lacking. To better understand the relationship between montelukast and neuropsychiatric events, it is vital to guide patients in the effective use of the drug, especially in children whose mothers are concerned about its side effects. In this study, randomized controlled trials (RCTs) investigating montelukast and neuropsychiatric events were retrieved from a literature search of the Medline (1966 to February 2023), Embase (1974 to February 2023), Web of Science, and other related databases. After screening, 18 RCTs were ultimately included in a meta-analysis to merge statistics, which demonstrated no significant increase in neuropsychiatric events compared with placebo. A similar pattern of adverse neuropsychiatric events was observed in patients grouped according to age, with headache being the most common adverse neuropsychiatric event. Overall, montelukast did not significantly increase neuropsychiatric events in patients with allergic rhinitis and/or asthma compared with placebo. Large-sample RCTs are needed to verify the association between neuropsychiatric events and montelukast use in children, and attention is also devoted to FDA warnings.
摘要：
使用孟鲁司特,作为神经精神事件的原因，在哮喘或过敏性鼻炎患者中存在争议，和全面的统计分析验证这种关系仍然缺乏。为了更好地理解孟鲁司特与神经精神事件之间的关系，指导患者有效使用药物至关重要，尤其是那些母亲担心其副作用的孩子。在这项研究中,研究孟鲁司特和神经精神事件的随机对照试验（RCT）从Medline（1966年至2023年2月）的文献检索中检索，Embase（1974年至2023年2月），WebofScience,和其他相关数据库。筛选后,18项随机对照试验最终纳入荟萃分析，以合并统计数据，与安慰剂相比，神经精神事件没有显着增加。在根据年龄分组的患者中观察到类似的不良神经精神事件模式。头痛是最常见的不良神经精神事件。总的来说,与安慰剂相比,孟鲁司特并未显著增加过敏性鼻炎和/或哮喘患者的神经精神事件.需要大样本随机对照试验来验证儿童神经精神事件与孟鲁司特使用之间的关联。和关注也致力于FDA的警告。
